| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Atreca, Inc. | GENERAL COUNSEL & SECRETARY | Class A Common Stock | 50.4K | $18.9K | $0.37 | Sep 1, 2023 | Direct |
| Maze Therapeutics, Inc. | GC and Corp. Secretary | Restricted Stock Units | 22K | Sep 22, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | Sep 22, 2025 | 1 | $0 | 4 | Sep 24, 2025 | GC and Corp. Secretary |
| MAZE | Maze Therapeutics, Inc. | Jan 30, 2025 | 0 | $0 | 3 | Jan 30, 2025 | GC and Corp. Secretary |
| BCEL | Atreca, Inc. | Sep 1, 2023 | 1 | -$2.65K | 4 | Apr 3, 2024 | GENERAL COUNSEL & SECRETARY |
| BCEL | Atreca, Inc. | Aug 2, 2023 | 1 | -$3.88K | 4 | Aug 4, 2023 | General Counsel & Secretary |
| BCEL | Atreca, Inc. | Feb 9, 2023 | 2 | $0 | 4 | Feb 13, 2023 | General Counsel & Secretary |
| BCEL | Atreca, Inc. | Sep 2, 2022 | 1 | -$11.4K | 4 | Sep 20, 2022 | General Counsel & Secretary |
| BCEL | Atreca, Inc. | Jun 13, 2022 | 8 | $0 | 4 | Jun 15, 2022 | General Counsel & Secretary |
| BCEL | Atreca, Inc. | Dec 23, 2021 | 1 | $0 | 4 | Dec 28, 2021 | General Counsel & Secretary |
| BCEL | Atreca, Inc. | Sep 9, 2021 | 1 | $0 | 4 | Sep 13, 2021 | General Counsel & Secretary |